Thelansis

 Pulmonary arterial hypertension (PAH) is a progressive and chronic condition marked by antiproliferative changes in the pulmonary arterioles, resulting in endothelial and smooth muscle proliferation and dysfunction, inflammation, and the formation of blood clots. PAH is primarily caused by remodeling pulmonary arteries, narrowing and obstructing the smallest arteries. This increased resistance in the pulmonary circulation results in elevated pressure within the right ventricle. Specific gene mutations, including BMPR2 (2q33), ACVRL1 (12q13), Endoglin (9q34), CAV1 (7q31), KCNK3 (2p23), Smad9 (13q12), and TBX4 (17q21), have been associated with heritable PAH. Most cases of PAH typically develop in adults, with occasional occurrences in children. Women are twice as likely as men to be affected by this condition. Initial symptoms include shortness of breath, fainting, chest discomfort, palpitations, and swelling in the lower extremities. Clinical signs include a prominent and palpable...

 Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by antiproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation, and thrombosis. As per Thelansis’ research, the total prevalent cases of Pulmonary Arterial Hypertension (PAH) in 8 major markets range from 129,857 in 2018 to 148,655 by 2030. Idiopathic PAH is the most commonly found form of Pulmonary Arterial Hypertension (PAH). A higher Prevalence of Pulmonary Arterial Hypertension is observed among females compared to males in 8MM countries. ·        Among the diseases associated with PAH, it was observed by the Thelansis research team that around ~50% of patients are associated with Connective Tissue Disease (CTD), ~19% have Congenital Heart Disease (CHD), and ~11% suffer from portal hypertension. ·        The current therapeutic landscape for ...